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ABSTRACT 
Patients with hematological malignancies have an increased risk of infectious complications. These 
complications can be caused by disease-specific factors or be treatment-related. Bloodstream 
infections increase the risk of morbidity, mortality, have a negative impact on quality of life, and may 
lead to reductions in treatment intensity. Surveillance studies on infectious complications and new 
technologies in diagnosing bloodstream infections are two important fields in improving management 
of patients with hematological malignancies. 
Paper I: This is a retrospective study of positive blood cultures from patients mainly treated with 
dose-intensive antitumoural treatment between 2002 and 2008. Bacterial distribution, bacterial 
resistance and mortality from 667 fever episodes are presented. Results are compared with historical, 
previous published, material from the same institution and setting. Subsequently, temporal trends from 
1980 to 2008 could be analysed. In a setting with very low use of fluoroquinolone-prophylaxis it can 
be concluded that; the distribution of Gram-positive bacteremia is stable, the crude mortality remains 
low in an international perspective and acquired resistance is uncommon but a significant increase in 
ciprofloxacin resistance in Escherichia coli is observed. The five most common bacteria in the study 
are; E. coli, coagulase-negative staphylococci, viridans streptococci, Klebsiella spp., and 
Staphylococcus aureus. 
Paper II: This is a retrospective study that investigated temporal trends in bloodstream infections in 
patients with chronic lymphocytic leukemia between 1988-2008. We find a decrease in positive blood 
cultures over time and speculate if this could be due to more effective antitumoural treatment in recent 
years. Moreover a bloodstream infection is, as intuitively foreseen, associated with worse prognosis. 
Dominating pathogens in the study are; E. coli, Streptococcus pneumoniae, P. aeruginosa, S. aureus, 
and viridans streptococci. Coagulase-negative staphylococcus, a common skin contaminant, is the 
most frequently detected bacteria.  
Paper III: This is a prospective study of 33 patients with aggressive hematological malignancies in 
need of dose-intensive chemotherapy. One hundred thirty blood samples were collected at different 
time points during episodes with neutropenia and fever between 2013 and 2014. Conventional blood 
culture findings were compared with a method applicable also for unculturable bacteria, 16S rRNA 
amplicon sequencing. Sequencing yielded reads belonging to Proteobacteria (55.2%), Firmicutes 
(33.4%), Actinobacteria (8.6%), Fusobacteria (0.4%), and Bacteroidetes (0.1%). The results display a 
much broader diversity of bacteria in bloodstream infections than expected. Changes in the relative 
abundance in the sequence data after commencement of antibiotics could be suggestive for a new 
method for estimating antibiotic efficacy. Lastly, the results are indicative for translocation, especially 
of gut microbiota, playing an important etiological factor in fever episodes in the neutropenic host.  
Paper IV: This is a prospective study of 9 patients with acute leukemia in which we applied shotgun 
metagenomics for 27 blood samples collected during episodes of neutropenia and fever between 2013 
and 2014. Shotgun metagenomics can characterize DNAemia and reconstruct unculturable microbial 
communities, resistance markers and gene ontology. The study confirms the method’s applicability in 
bloodstream infections demonstrating bacteria, viruses and fungi. Furthermore, the observed dynamics 
of microbe sequences during fever episodes as well as gene ontology makes this diagnostic approach 
appealing for exploring the fever episodes in this patient category.  
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1 INTRODUCTION 
Hematological malignancies, as a group, are the fourth most common cancer in Sweden. Yearly, 
approximately 2,400 patients are diagnosed, which is 7% of all diagnosed malignancies; a 
proportion comparable with other developed countries (1, 2). Hematological malignancies are 
responsible for approximately 8% of cancer-related deaths in Europe (3). Patients with 
hematological malignancies have increased risk for infectious complications attributed to inherent 
disease-, host-, and therapy-related factors. Also, serious infectious complication as the direct cause 
of death is a common manifestation of an end-stage, often refractory, hematological malignancy (4). 
In high-risk settings, such as after allogeneic stem cell transplantation (alloSCT), the cumulative 
incidence of death attributed to infection has significantly decreased over the years. However, 
infectious-related death within a year still remains at 1% for those transplanted between 1999 and 
2001 (5). In low-income countries the risk of infection related death after antitumoural treatment is 
even higher (6). In addition, an infectious complication is an important cause of morbidity causing 
dose reduction and treatment delays, negatively effecting outcome (7). 
The view of infectious complications and causative pathogens, in bloodstream infections (BSI) in 
particular, have changed over the last decades due to changes in antitumoural treatments, use of 
indwelling catheters, antimicrobial prophylaxis, and vaccination. BSI can be caused by bacteria, 
viruses and fungi. Sepsis is characterised by a life-threatening organ dysfunction caused by a 
dysregulated host response to infection (8). Microbial invasion of the bloodstream or the release of 
microbial products results in the deleterious host response. Sepsis ranks among top ten causes of 
death (9). Delayed initiation or delayed specific coverage of pathogens decreases the survival rate of 
patients with sepsis several-fold (10-12). 
Knowledge of the local panorama of infectious complications and antibiotic resistance are essential 
parts of management of hematological malignancies. Today, effective treatment of suspected 
infectious complication is hampered due to limitations of diagnostic methodologies. For example; 
results of blood cultures might take days to receive and can only detect culturable bacteria and 
polymerase chain reaction (PCR) for pathogen detection in blood is associated with several problems 
regarding interpretation and accuracy, to mention a few (13).  
Genome information derived from next generation sequencing (NGS) has revealed important 
information for hematological malignancies and will pave the way for personalized medicine (14). 
NGS offers, in the context of microbiology, means for identifying viable, dead and viable but 
unculturable bacteria, fungi and viruses. Moreover, NGS can retrieve information about resistance 
markers, virulence, antimicrobial treatment effect, new pathogens, and host-microbiome 
interactions, and hopefully unravel fever episodes where traditional microbial diagnostics have 
failed (15). 
Management of suspected fever and prevention of infectious complications will doubtless also in the 
future be a challenge, and hopefully, a field of continuing improvement regarding the care of patients 
with hematological malignancies. 
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2 BACKGROUND 
Hematological malignancies can be subdivided in numerous ways; for practical reasons and in 
regard of the patient population under study the following major subgroups are presented: acute 
myeloid (AML) and lymphoblastic leukemia (ALL), chronic myeloid (CML) and lymphocytic 
leukemia (CLL), and aggressive-, indolent non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma 
(HL) (Figure 1). Epidemiology is presented in Figure 2.  
Figure 1. Hematological malignancies, adapted from Dr Dinesh Bhurani (16). 
2.1 ACUTE LEUKEMIAS 
Acute leukemia is characterized by the neoplastic proliferation of precursors to myeloid and 
lymphoid blood cells, respectively. The immature blast cells accumulate in the bone marrow and 
suppress normal hematopoiesis resulting in anemia and thrombocytopenia. Blast cells may or may 
not enter the bloodstream (leading to either high or low leukocyte counts) and can infiltrate other 
organs. Common manifestations of leukemia are fatigue (related to anemia), bleeding (due to 
thrombocytopenia) and infection due to secondary effects on the immune system. 
2.1.1 Acute myeloid leukemia 
AML is the most common form of acute leukemia in the adult, constituting 80% of leukemias in 
this group. This is contrast to the situation for children with acute leukemia, where <10% are AML 
(17). The majority of patients with AML receive dose-intensive chemotherapy resulting in profound 
immunosuppression: median time of neutropenia (absolute neutrophil count (ANC) <0.5×10
9
/L) is 
approximately 10 days (18). Prognosis is dependent on patient-related factors like age, performance 
status and comorbidities as well as diseases-related factors like cytogenetic aberrations. In general, 
children and elderly (>60 years) individuals have a poorer prognosis with overall survival of 
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approximately 65% and <13%, respectively (19, 20). Treatment is often divided into an induction 
phase, and a consolidation phase. The induction phase aims to eradicate the malignant cells, to 
induce a so-called complete remission, and is successful in this in over 60-90% in adult patients <60 
years. A complete remission is often defined as ≤5% blast in the bone marrow with recovery of 
ANCs and thrombocytes. Consolidation treatment aims to reduce risk for relapse, which is 
substantial. This can be done through chemotherapy alone or in conjunction with autologous stem 
cell transplantation (autoSCT) or alloSCT. The cytotoxic regime given with stem cell 
transplantation mandates stem cell rescue to renew hematopoietic cell. Stem cell can either be the 
patient’s own stem cells (autologous stem cells) or originate from a matched donor (allogeneic stem 
cells). 
Figure 2. Epidemiological differences in hematological malignancies. Incidence and median age for adults were retrieved 
from National quality registries for respective diagnosis and estimated deaths per year were extracted from National Cancer 
Institute’s (United States of America) database. Only for aggressive NHL (agg. NHL) death rate was retrieved form The 
National Board of Health and Welfare <Diffuse large-b-cell lymphoma>. AML (21, 22), ALL (23, 24), CML (25, 26), CLL 
(27, 28), agg. NHL (29, 30) and HL (31, 32). 
2.1.2 Acute lymphoblastic leukemia 
ALL is a clonal disease characterized by B-or T-cell origin. Leukemia is the most common 
malignancy in children (approximately 25% of all new cases) and the majority (90%) of pediatric 
leukemias are ALL. Even though remission rates of 80% (only slightly lower than for children) can 
be achieved in the adult setting the long term survival is only about 10%, which is in sharp contrast 
to the children setting (33). Bad prognostic markers are age (usually above 35 years), white blood 
count (usually greater than 30×10
9
/L) and some cytogenetic aberrations. Approximately 30% of 
ALL carry the 9;22 chromosome translocation associated with poor prognosis that is also 
commonly (>90%) found in CML. Treatment constitutes of several antitumoural agents for 
intravenous and intrathecal administration. Also in ALL, high-risk patients can be subjects for 
alloSCT.  
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2.2 CHRONIC LEUKEMIAS 
Chronic leukemias are commonly divided into CML and CLL, although other rare forms exist. 
Great progress in management has been made in the last decades (34, 35).  
2.2.1 Chronic myeloid leukemia 
CML is a clonal disease characterized by proliferation of mature granulocytes (neutrophils, 
eosinophils and basophils) and their precursors. The prevalence of CML is increasing due to 
introduction of effective treatment with tyrosine kinase inhibitors (TKI) (36). CML can be divided 
into three subgroups: chronic phase, accelerated phase and blastic phase. Patients in the two latter 
groups have the worst prognosis. According to the Swedish population-registry patients at diagnosis 
belong to corresponding group in 93%, 5% and 2%, respectively (37). For chronic phase CML 
standard therapy is lifelong TKIs. Interestingly, reports on discontinuation of TKI treatment with 
very good treatment free progression results are now appearing (38). For those patients that cannot 
tolerate or achieve a good response on TKI in chronic phase (and some in low risk accelerated 
phase) as well as those in blastic phase, alloSCT offers the best option for long-term survival (39). 
Patients in need of quick blast reduction, for example before alloSCT, are offered AML–like 
treatment. Patients with CML in chronic phase do not have an increased risk for infections (40). 
2.2.2 Chronic lymphocytic leukemia 
CLL originate from mature lymphocytes, most commonly B-lymphocytes. The natural history of 
CLL varies considerably: less than 30% of CLL patients never progress and die from an unrelated 
cause (41). Prognosis can be estimated with regard to disease stage, blood counts and cytogenetic 
abnormalities. Antitumoural management has constantly changed the last 25 years, and is still 
dynamic (42). Treatment today consists of chemotherapeutic agents (purine analogs and alkylating 
agents) and monoclonal antibodies (alemtuzumab, rituximab, ofatumumab and obinutuzumab). 
Recently cellular signaling pathway inhibitors have been approved, the Bruton tyrosine kinase 
inhibitor ibrutinib, phosphatidylinositol-3 kinase delta inhibitor idelalisib and the Bcl-2 inhibitor 
venetoclax, that substantially change the options for refractory, relapsed, comorbid, or elderly CLL 
patients. New check point inhibitors and engineered T-cells are in advances clinical trials. For 
physically fit patients with refractory CLL or with a high risk disease (i.e del17p or TP53 
mutations) alloSCT might be an option if they relapse after a kinase inhibitor and respond to 
subsequent treatment. The pathogenesis of infections in CLL patients is multifactorial, and is related 
to inherent immune defects and therapy-related immunosuppression (43).  
2.3 LYMPHOMAS 
Lymphomas are a diverse group of malignant neoplasms that can be divided in indolent and 
aggressive NHL and HL (Figure 1). NHLs are derived from B cell progenitors, T cell progenitors, 
mature B cells, mature T cells, or (rarely) natural killer cells. HL arises from a neoplastic B cell that 
is surrounded by inflammatory cells. 
2.3.1 Indolent non-Hodgkin lymphoma 
Indolent NHLs represent a big heterogeneous group of insidious lymphomas often presenting with 
lymphadenopathy, hepatosplenomegaly, or cytopenia. Typical examples of NHL are follicular 
lymphoma, CLL/small lymphocytic lymphoma (SLL) and splenic marginal zone lymphoma. 
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CLL/SLL is considered the same entity but with different manifestation (the latter predominantly in 
lymphoid tissue outside the bone marrow compartment). There has been major improvement in 
therapeutic options but careful monitoring of asymptomatic patients remains the golden standard of 
management. Cure is often not possible but long time survival is common and risk of infectious 
complications varies widely (44). 
2.3.2 Aggressive non-Hodgkin lymphoma 
About half of NHLs are aggressive (45). If untreated, patients with aggressive NHL will succumb 
within weeks to months. Patient history often reveals typical associated night sweats, weight loss, 
fever and a rapid growing mass; and an elevated level of lactate dehydrogenase is often observed. 
Examples of aggressive lymphomas are diffuse large B cell lymphoma (25-30% of all lymphomas), 
Burkitt lymphoma, adult T cell leukemia/lymphoma, and precursor B- and T-lymphoblastic 
leukemia/lymphoma (46). Antitumoural treatment, often aiming for cure, constitutes of 
immunochemotherapy and in selected cases SCT, leading to a subsequent increased risk of serious 
infectious complications. 
2.3.3 Hodgkin lymphoma 
HL, accounts for <10% of all lymphomas (17). Classical prognostic factors are age, stage, tumor 
location, histology, and comorbidities. Primary antitumoural treatment for HL includes combined 
modality treatment (including radiotherapy and chemotherapy) for localized HL while patients with 
advanced disease will receive dose-intensive chemotherapy (47). Intensified chemotherapy 
followed by autoSCT is indicated if residual tumour activity or relapse is seen (48). Antibodies 
targeting CD30, small molecule inhibitors of cell signaling, and antibodies that inhibit immune 
checkpoints, have all demonstrated activity in HL (49). 
2.4 ETIOLOGY OF BLOODSTREAM INFECTIONS 
2.4.1 Definitions and incidence of bloodstream infections 
BSI is defined as a positive blood culture in conjunction with symptoms of infection. 
Fever is in clinical practice defined as a single oral (or tympanic) temperature of >38.3°C or 
temperature of ≥38.0°C sustained for 1 hour (50). 
Neutropenia is herein defined as an ANC of <0.5x10
9
/L, or a count expected to decrease to 
<0.5x10
9
/L over the next 48 hours. 
Fever accompanying therapy-induced neutropenia affects approximately 80% of those with 
hematological malignancy. A BSI is identified in 10-25% of fever episodes after chemotherapy, and in 
up to 60% following SCT (50-52). During therapy-induced neutropenia, the crude mortality rate of 
BSI is about 15% (53, 54).  
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2.4.2 Taxonomy of microorganisms 
Figure 3. The taxonomy of bacteria based on the work of Carl von Linné (55). 
Based on Carl von Linné’s work, organisms are categorized into three domains: eukarya, bacteria and 
archae. The domain eukarya encompasses several kingdoms, for example fungi and animals. The 
domain of bacteria consists of 30 phyla which can be further subcategorized into class (for example 
bacilli), order (for example Lactobacillalles), family (Lactobacillaceae), genus (Lactobacillus), and 
species (L. delbrueckii) (Figure 3). 
2.4.3 Bacteria 
The vast majority of all BSI constitutes of bacteria. Historically, S. aureus was the most common 
cause of fatal infection in patients undergoing leukemia treatment. Following the introduction of 
routine use of β-lactam antibiotics Gram-negative bacteremia, E. coli, Klebsiella spp., and P. 
aeruginosa dominated in the 1960s and mid 1970s (56). Resistance was low and empirical treatment 
often constituted of penicillin, or a first generation cephalosporin, with or without an aminoglycoside. 
During the 1980s and early 1990s Gram-positive bacteria; CoNS, S. aureus, enterococci and viridans 
streptococci dominated (57). During the last two decades our center showed a stable Gram-positive 
distribution (58), but others in Europe and elsewhere, again, report increasing Gram-negative 
proportions (59-61). 
2.4.4 Fungi 
Both yeasts and moulds are associated with an increased morbidity and mortality risk in 
immunocompromised patients. Invasive fungal infections (IFI) are not infrequently found at 
autopsy, and only seldomn detected ante mortem (62). Neutropenia (for >10 days), SCT, prolonged 
treatment (>4 weeks) with corticosteroids, drugs or conditions that lead to chronically impaired 
cellular immune responses are some of the more major risk factors for IFI. In the hematology 
setting Candida spp., Aspergillus spp., Zygomycetes, Cryptococcus spp. and Fusarium spp. are the 
most commonly occurring pathogens (63). Conventional histopathological examination and 
mycological methods for identification (direct microscopy or culture of samples) are often not 
possible (due to for example thrombocytopenia and need of invasive procedures) or associated with 
low sensitivity. Nevertheless, a positive culture with susceptibility testing can help to optimize 
treatment (64). Treatment delays dramatically correlate with increased mortality rates, and therefore 
molecular methods and algorithms for assessing fungal risk have been developed (65, 66).  
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1,3-Beta-D-glucan (BDG) is a cell wall component found in a wide variety of fungi that can be 
analysed from blood; notable exceptions are Cryptococcus spp. and Zygomycetes (67, 68). Its 
favorable negative predictive value could be useful in high risk setting, although, high rates of false 
positive results of BDG test hampers its utility (69). Galactomannan, another cell wall component 
that can be sampled from blood, is relatively specific for Aspergillus spp. but the test, as BDG, is 
associated with false positive results (moderate sensitivity) (70).  
PCR based methods for identification of fungi are rapid and promising, with high sensitivity and 
specificity (71, 72). Lack of standardization, difficulty in distinguishing between contamination and 
true IFI are some of the issues that need to be solved. The ongoing optimization of algorithms for 
diagnosing IFI will probably use combination of techniques to improve antifungal treatment (73, 
74). 
2.4.5 Viruses 
In 70-90 % of fever episodes accompanying neutropenia no causative microorganism can be 
identified in blood cultures (75). In a study from our department a viral finding (nasopharynx 
aspirate or blood) was found in 42% of the fever episodes (76). However, not all viruses give rise to 
fever and finding a virus with a low titer might have no clinical consequence (77).  
Viral infections of importance, developing in the neutropenic time period, include cytomegalovirus 
infection, herpes virus, varicella zoster virus infection and community acquired respiratory virus 
infection. 
2.4.6 Catheter related infections 
Various forms of intravascular devices are essential in the management of patients with hematological 
malignancies receiving chemotherapy, transfusion therapy or parenteral nutrition. Central venous 
catheters can be non-tunneled (fixed in place at site on insertion) or more preferred tunneled (passed 
under skin from insertion). A subcutaneous port has a membranous septum under the skin and is 
accessed through intact skin. Among the more serious complications are central line-associated 
bloodstream infections. This is commonly defined (without the removal of the catheter) as growth of 
the same bacteria in cultures drawn from peripheral and central lines, with the growth of the bacteria 
in the central line growing two hours earlier than in the peripheral culture, and with no other apparent 
site of infection other than the catheter (78).  
2.5 ANTIBACTERIAL TREATMENT 
Classic signs of infection might be missing due to the immunocompromised host’s inability to 
mount an adequate inflammatory response, or concomitant steroids or other anti-inflammatory 
medication. The aim of the empirical treatment is to cover the most likely and virulent pathogens. 
Choice of treatment also needs to take into account the patient’s history, allergies, signs, symptoms, 
recent microbiological findings, antibiotic use and antibiotic resistance. International guidelines 
advocate empirical antibacterial therapy to be initiated in patients with suspected neutropenic sepsis 
without delay or within 60 minutes from presentation (79-81). 
Regular monitoring of local pathogens and antibiotic resistance is pivotal in clinical care of 
immunocompromised patients. 
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Internationally, the following different antibacterial approaches have been applied for inpatient 
treatment: 1) combination of penicillin and an aminoglycoside 2) monotherapy with third or fourth 
generation cephalosporin 3) combination of a third or fourth generation cephalosporin and an 
aminoglycoside 4) triple combination therapy containing a combination of a third or fourth 
generation cephalosporin, aminoglycoside, and glycopeptides (50, 82, 83). 
During recent years a more risk-adapted approach for choosing antibacterial treatment, venue and 
route of administration, has gained popularity. An example is the validated Multinational 
Association for Supportive Care in Cancer risk index (MASCC risk index score) (50, 84). Risk-
stratification allows the identification of a sub-population of neutropenic fever patients who can be 
treated at home with either intravenous monotherapy (often ceftriaxone, dosing once daily) or oral 
antibiotics (often a combination of fluoroquinolone + amoxicillin-clavulanate, or fluoroquinolone 
monotherapy). 
Moreover, in the general intensive care unit 15-30% of patients with BSI are estimated to receive 
inappropriate empirical antibiotics (85). In patients with hematological malignancies inappropriate 
empirical therapy of BSI has been associated with inferior outcome (86).  
Interestingly, in our inpatient ward for hematology patients at Karolinska University Hospital in 
Solna (HCK Solna) daily defined dose (DDD) of antibiotics have changed in the last decade (Figure 
4). In the beginning of the period the ward had 24 beds, dropping throughout the period, and in the 
end of the period approximately 14 beds remained. The proportions hematological diagnoses have 
though been stable. The DDD of meropenem and piperacillin-tazobactam has increased 
counterbalancing the decrease of ceftazidime, probably reflecting the notion that ceftazidime has a 
poor effect against viridans streptococci. Around 2006-2007 an increase of ciprofloxacin, our most 
commonly prescribed fluoroquinolone, was observed reflecting a change in policy of antibiotic 
prophylaxis in high risk patients. The peak between 2013 and 2014 in the use of ciprofloxacin could 
reflect an extreme situation where the HCK Solna and Karolinska Solna were short of beds for 
Figure 4. DDD of prescribed antibiotics from the hematology inpatient ward, Karolinska Solna between 2002 and 2015. 
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Figure 5. (A,B,C) Pattern of resistance for P. aeruginosa. 
patients with subsequent locally broadened indication of ciprofloxacin to also include less high risk 
situations.  
2.6 ANTIBIOTIC RESISTANCE 
Resistance patterns for bacterial BSI in hematological patients follow the resistance patterns of their 
countries in general. International generalization on outcome of infectious complications is therefore 
hampered.  
2.6.1 Gram-negative bacteria 
Among the Gram-negative pathogens, resistance to P. aeruginosa, E. coli, Klebsiella spp., 
Enterobacter spp. are of special interest. In our practice the majority of episodes of neutropenic fever 
episodes are initiated on empirical broadspectrum antibiotics including anti-pseudomonal coverage, 
often with piperazillin-tazobactam or carbapenem, according to local guidelines. Figures 5,6 and 7 
illustrate resistance trends for P. aeruginosa, E. coli, and Klebsiella spp. based on; blood cultures 
taken between 2002 and 2008 from HCK Solna, the Karolinska University Hospital Solna (Karolinska 
Solna) reported data, and nationally reported data to the “Antimicrobial resistance interactive 
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database“ of the European Centre for Disease Prevention and Control (ECDC) (58, 87, 88). 
Stenotrophomonas maltophilia is inherently resistant to most antibiotics except trimethoprim-
sulfamethoxazole and ticarcillin-clavulanate (89). Enterobacter spp. is together with the other 
Enterobacteriaceae important carriers of extended-spectrum β-lactamases (ESBLs). ESBLs can break 
down penicillins, cephalosporins, monobactams and sometimes carbapenems (90). Growth of ESBL 
producing bacteria is by law required to be reported to a national registry. ESBL incidence is 
increasing in Sweden (Figure 8). For Acinetobacter spp. resistance mechanisms for merely all 
antibiotics have been described (91). 
Figure 6. Pattern of resistance for E. coli. 
 
Figure 7. Pattern of resistance for K. pneumoniae. 
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2.6.2 Gram-positive bacteria 
Among the Gram-positive pathogens, resistance to staphylococci and enterococci are of special 
importance. CoNS is among the most frequently identified pathogen in BSI, but is associated with a 
very low morbidity (92). Nationally reported methicillin-resistant S. aureus (MRSA) to ECDC has 
been constantly low (≤1%) for the last decade. However the incidence is increasing (Figure 8). 
Enterococcus species, colonizing the intestinal tract, are considered to possess low virulence, but they 
are significant in terms of multi-drug resistance, predominantly vancomycin-resistant enterococci 
(VRE) (Figure 8). From 2009 to 2015 VRE in blood culture has been documented on one occasion at 
Karolinska Solna. Nationally reported incidence of VRE to the ECDC for the last decade is <1% (87, 
88).  
 
Figure 8. Notifiable resistance in Sweden from 2009 to 2015(Public Health Agency of Sweden 
(www.folkhalsomyndigheten.se)) 
3 DIAGNOSING BLOODSTREAM INFECTIONS 
3.1 BLOOD CULTURE 
Blood cultures are routinely drawn from patients with suspected BSI. Among positive blood 
cultures bacteria are most commonly found but also fungi can be found. Despite the knowledge of 
the importance of a positive blood culture little has changed in methods of blood culturing, even 
though incremental progress has been made in pathogen identification by other techniques and 
susceptibility testing. Continuous blood culture monitoring systems, in Karolinska University 
Hospital BacT-ALERT (bioMérieux, France), were introduced in the 1990s. Inoculated blood 
culture vials are loaded on the system, incubated, and monitored for production of CO2. A change in 
CO2 concentration implies biological activity and a positive signal is generated for a predefined 
threshold. Positive vials are removed from the system and stained with Gram stain to differentiate 
Gram-positive and Gram-negative organisms. Additional microscopy studies can reveal additional 
characteristics (morphology and growth pattern) that aid the microbiologist in an early attempt (<12 
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hours from drawn blood culture) to guide empirical antibiotic therapy. After Gram stain, culture 
plates can be removed for an attempt of direct identification, based on biochemical characteristics, 
and susceptibility testing. However, sensitivity is less than using cultured colonies of 
microorganisms. With conventional methods, a preliminary report on bacterial identification and 
susceptibility can be made after 18-24 hours and a more definitive usually after 24 hours. Standard 
incubation in automated monitoring blood culture systems is 5 days. 
Guidelines recommend, whenever possible, two to four sets of blood culture bottles to be collected. 
Viable microbial concentrations in patients with BSI are low and recovered microbial yield is 
proportional to drawn blood culture volume (93-95). Several key factors may lower contamination 
rates (goal is <5%): adherence to protocols, sampling from peripheral vein compared to through 
central venous access, use of sterile gloves, using antiseptics on tops of blood culture bottles and 
using dedicated phlebotomy teams (96-99). 
Recovering fungi from blood cultures can be more troublesome, as the optimal growth temperature 
and blood culture media varies. Most automated blood culture systems enable growth of yeast, for 
example Candida spp. But if the suspicion is strong for yeast, dimorphic fungi or moulds alternative 
culture methods should be employed (100). Finally, blood culture growth is impeded in patients on 
antibiotics and polymicrobial bacteremia (101).) 
With above-mentioned limitations for different microorganisms, interpreting a positive blood 
culture is rarely problematic. In case that a majority of independent drawn blood culture bottles are 
positive with the same microorganism, the likelihood for a true (i.e. not contamination or unknown 
significance) BSI is extremely high. Additionally, isolations of certain organisms are also 
predictive: S. aureus, Enterobacteriaceae, S. pneumoniae, P. aeruginosa and Candida albicans 
represent almost always a true BSI. Conversely, from a multicenter study CoNS was isolated in 
38% of positive blood cultures but was only considered a pathogen in 10% of cases (102). 
Similarly, very few of Corynbacterium spp., Bacillus spp., Micrococcus spp., Lactobacillus spp. 
and Propionbacterium spp. were considered true pathogens. In a high risk clinical setting, as 
immunocompromised patients with a hematological malignancy, BSI for skin pathogens mostly 
requires two positive sets with the same antibiogram or that pathogens are associated with 
appropriate clinical findings when available (61, 103). 
3.2 MUTLIPLEX POLYMERASE CHAIN REACTION 
Current methods for diagnosing bloodstream infection are limited in their diagnostic capabilities 
and timeliness. Molecular methods that target conserved regions of microbial genomes for 
amplification have been developed. Although they were shown to be useful for detecting blood 
culture-negative endocarditis (104), no PCR-system has yet, been described to replace blood culture 
in the setting of BSI due to mainly low and thus unsatisfactory specificity (105, 106). 
3.3 MATRIX-ASSISTED LASER DESORPTION/IONIZATION TIME-OF-FLIGHT 
MASS SPECTROMETRY 
It was proposed already in 1975 that the mass spectrometry could be used in microbiology (107). 
The last two decades commercial use of Matrix Assisted Laser Desorption/Ionization Time-of-
Flight Mass Spectrometry (MALDI-TOF MS) was enabled by the discovery of, by the Nobel Prize 
laureate Kochi Tanaka in 1985, its use on macromolecules. MALDI-TOF MS process begins with 
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that a microbial colony, or processed clinical specimens, are mixed with a chemical matrix on a 
MALDI-plate, crystallized and pulsed with a laser (108). The matrix facilitates the ionization 
process. The laser energy ionizes and ablates the molecules form the sample. In the next phase the 
time the different molecules travel in an electric field is recorded by the spectrometer. Large 
molecules travel slower and signal can be converted in a mass (in Dalton) and its intensity 
correlated with abundance. The mass of the molecule is then checked against a database for 
phylogenetic characterization. In microbiology MALDI-TOF MS enables quick identification 
(minutes) of many clinical relevant bacteria and fungi with low false positive results to a low cost. 
Comparing MADI-TOF MS identification of bacteria to the species and genus level with traditional 
blood cultures reveals concordance in 80.1 and 87.7%, respectively, for Gram-negative better than 
for Gram-positive, and for fungi even better (109-111). Some species, already hard do differentiate 
with biochemical methods, are also hard to distinguish with MALDI-TOF MS due to close 
relationship, like for example differentiating Streptococcus mitis group and S. pneumoniae, Shigella 
spp. and E. coli, and Listeria spp. from each other. Lastly, MALDI-TOF MS has been shown to be 
less reliable in polymicrobial bloodstream infections (109). Coupling PCR with mass spectrometry 
has recently been explored for diagnosing bloodstream infections with promising results (112). 
3.4 METAGENOMICS 
Understanding microbial diversity has been the goal for scientists for decades, but these studies 
focused only on culturable bacteria. Genomics, with the use of NGS, is a relatively new technology 
that uses recombinant DNA, DNA sequencing and bioinformatics to analyse the genome. 
Metagenomics can characterize the genome of microbial communities directly from the 
environment, as for example the human blood or stool.  
The human body contains approximately equal numbers of bacteria and human cells and the human 
microbiome (bacteria, viruses and fungi) is important in maintaining health (113). Genome 
characterization started with the bacteriophage by Sanger sequencing in the 1970’s (114). In 1986 
the first automated apparatus for capillary electrophoresis was introduced which could deliver 
1,000bp/day. Until 2005, with developments in sequence terminator chemistry and moving from 
gel- to capillary electrophoresis with obtainable sequence lengths of ~800bp, Sanger sequencing 
was the dominant sequencing technique. In 1995 the first whole genome of a strain of Haemophilus 
influenzae was sequenced and in 2001, the human genome (115, 116). Since 2005 methods have 
developed that massively increase the sequence data, therefore called NGS (117). The platforms 
share core similarities: 1) no cloning of DNA is required 2) DNA templates are spatially segregated 
and no physical separation step is needed and 3) DNA is sequenced through synthesis. Platforms 
differ in how to build template libraries, generating a signal, throughput (amount of sequenced bp 
pair per run), read lengths and error rates.  
The two main approaches for identifying microorganisms remain the amplicon sequencing (mostly 
restricted to the 16S ribosomal RNA (16sRNA) or 18S ribosomal RNA in bacteria and fungi, 
respectively) and shotgun metagenomics, which allows untargeted sequencing of DNA in a given 
sample. Major challenges in metagenomics of human blood samples include 1) low pathogen DNA 
load versus human DNA 2) inhibitory compounds in whole blood, and 3) contamination and/or 
bacterial origin from certain reagents (118, 119). Furthermore, most commercial products for 
identification of microorganism do not immediately report on the viability of the identified 
microbes. Retrieving viability information requires additional analyses as for example, repetitive 
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measures (to quantitate bacterial DNA clearance quantitatively) or dyeing the DNA with propidium 
monoazide (dye only binds to compromised membranes), which inhibits PCR amplification (120). 
3.5 AMPLICON SEQUENCING: 16S RIBOSOMAL RNA  
The 16sRNA gene, around 1,550bp long, is present in all bacteria and is composed of interspersed 
variable regions flanked by relatively conserved regions. Probes can be designed to hybridize the 
conservative regions of the extracted DNA for PCR amplification, and subsequent sequencing of 
the variable regions allows identification of different bacteria. For most clinical isolates, the initial 
500bp is enough for bacterial differentiation (121). For the Illumina technology, used in our 
laboratory, the next step is a simultaneous tag- and fragmentation. The modified molecule bounds to 
the complementary oligonucleotide on a flow cell. Next step is a parallel synthesis of a library that 
can work as a template for the fluorescently tagged nucleotides during sequencing. Only one 
complementary fluorescent nucleotide can bind per cycle, the rest is washed away. At the end of a 
cycle a camera takes a shot of the chip and a computer can, based on the wavelength and intensity 
emitted, determine which base and where it was produced.  
Bioinformatic analysis begins with quality checking and preprocessing of reads. Reads with similar 
base calls are aligned and those who are similar are clustered, forming operational taxonomic units 
(OTUs). OTUs are defined by how the sequences under a particular percentage diverge from each 
other. OTUs are annotated by comparison with well-known database libraries via analytic software 
tools or the World Wide Web, for example from the Ribosomal Database project (122). 
3.6 SHOTGUN METAGENOMICS  
With shotgun metagenomics the entire DNA content of a sample, instead of a targeted locus, is 
fragmented, and then the fragments are sequenced in parallel. The way reads are produced depends on 
which NGS-method is used. In metagenomics the reads usually vary between 100 and 400bp, 
depending on the NGS-method used. Reads with similar base calls are assembled, forming contigs, 
Taxonomic information is ascribed to each contig by sequence comparison with well-known 
database libraries via the World Wide Web, for example GenBank (http://www.ncbi.nlm.nih.gov/) 
for identification and variant analysis. Potentially, shotgun metagenomics can not only describe 
taxonomic diversity, but also functionality, since entire microbial genes can be assembled (123).    
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4 STUDY AIMS 
With the goal of improving management of infectious complication in patients with hematological 
malignancies studies with the following objectives were conducted 
 
Retrospective epidemiological studies  
 Defining trends in bacterial BSI: pathogen distribution, antibiotic resistance and mortality in 
patients with aggressive hematological malignancies in general (I) 
 Defining bacterial distribution and mortality in BSI in patients with CLL (II) 
 
Prospective comparative cross-sectional and longitudinal studies  
 Revealing bacterial DNA in BSI in hematological malignancies during chemotherapy-
induced neutropenia by the use of NGS and conventional methods (blood cultures) (III) 
 Investigating microbial DNA in BSI at different time points during chemotherapy-induced 
neutropenia in hematological malignancies (IV) 
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5 RETROSPECTIVE COHORT STUDIES (I, II) 
5.1 MATERIAL AND METHODS 
5.1.1 Study I 
In this study we investigated 10,071 blood cultures from 1,855 patients sampled between 2002 and 
2008 from HCK Solna. Out tertiary urban hospital offers a variety of antitumoural treatments for 
adults according to national guidelines, excluding alloSCT. For temporal trends patients were 
compared with earlier published data (1980-86 and 1988-2001) from the same institution. Roughly, 
1/3 of patients were diagnosed with malignant lymphoma, 1/3 with leukemia and 1/3 with myeloma 
and CLL. Sampling indication and procedures have been unchanged during observed periods. 
Study patients were identified through the laboratory information system. Antimicrobial prophylaxis, 
most importantly fluoroquinolone-prophylaxis, has been low and unchanged during investigated and 
compared study periods. Laboratory procedures for detecting positive blood cultures were automated 
in 1993. 
A positive blood culture was defined by the presence of bacteria (1) other than typical skin 
contaminants in at least one blood culture or (2) in two blood cultures from the same fever episode 
(same day). A polymicrobial bacteremia episode was defined by growth of more than one bacterial 
species within 24 hours. Growth of the same bacteria <7 days was not considered a new positive blood 
culture. 
Isolated strains had antibiogram determined; either as susceptible (S), intermediate (I) or resistant (R), 
according to the Swedish Reference Group for Antibiotics. Isolated bacteria was considered resistant 
(I or R) if reduced susceptibility was observed in isolates belonging to the following species: 
imipenem, piperacillin-tazobactam or metronidazole for anaerobic bacteria; piperacillin-tazobactam, 
ceftazidime or ciprofloxacin for Enterobacteriaceae and Pseudomonas spp.; vancomycin for 
Enterococcus faecium; isoxazolyl-penicillin for S. aureus; trimethoprim-sulfamethoxazole for S. 
maltophilia; and benzyl-penicillin for viridans streptococci, β-hemolytic streptococci and S. 
pneumoniae. Due to lack of adequate methodology for studying low-grade vancomycin resistance in 
staphylococci in previous years (disc diffusion can only detect high-grade resistance) a proper 
comparison of resistance levels could not be conducted. 
For statistical analysis comparing categorical variables we used the two-tailed Fisher’s exact test. P-
values <0.05 were considered statistically significant 
5.1.2 Study II 
Individuals who had a blood culture analysed between 1988 and 2006 at the Karolinska University 
Hospital’s Clinical Microbiology Laboratory were linked to national Swedish Cancer Registry (ICD 
7 204.1). 275 patients (1,092 blood cultures) had a preceding diagnosis of CLL. 
A bloodstream infection was defined as growth of any microorganism excluding common skin 
contaminants. Growth of the same microorganism within seven days was considered as the same BSI 
episode. Identified individuals were linked to nationwide Cause of Death Registry to retrieve 
information on death and the Swedish Patient Registry to retrieve discharge diagnosis. Depending on 
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year of diagnosis individuals were grouped into three separate time periods 1988-1993, 1994-1999, 
and 2000-2006. 
Survival analysis with BSI as exposure were analysed both as a dichotomous and time-varying 
variable. Cox proportional regression models were used to calculate risk hazards in the three different 
timer periods. A sensitivity analysis, including patients diagnosed within a year of their bloodstream 
infection was made to evaluate potential selection bias. For patients undergoing splenectomy survival 
was evaluated in a separate model. 
Differences in proportion of BSI between time periods were tested using chi-square test or Fisher’s 
exact test. Differences in mean time to blood culture were tested using a t-test. 
5.2 RESULTS AND DISCUSSION  
5.2.1 Study I 
When this study was initiated there was no consensus on antibacterial prophylaxis for dose-intensive 
chemotherapies in hematological malignancies (124), except for those at risk of Pneumocystis 
jirovecii pneumonia. Our study group had demonstrated, in our center, a low prevalence of bacterial 
resistance, stable distribution of pathogens and a stable Gram-positive to Gram-negative distribution. 
A Cochrane meta-analysis by Gafter-Gvili et al., first published in 2005 (and later updated in 2007 
and 2012) presented a reduced risk by 48% (95% CI 33% to 65%) in infectious related death in the 
fluoroquinolone-prophylaxis group compared to placebo; but also significantly with respect to overall 
mortality, fever and clinically documented infections (125). Meanwhile reports internationally implied 
an increase in Gram-positive bacteria among hematological patients receiving quinolone-prophylaxis 
(126), and an increase in fluoroquinolone-resistance in the community (127). 
For above reasons, we therefore performed study I. Between 2002 and 2008 we found 794 relevant 
isolates in 463 patients, making 667 bacteremia episodes (Table 1). Compared with earlier published 
results from the same institution 1980-1986 and 1988-2001 the proportion of positive blood cultures 
and ratio Gram-positive to Gram-negative were stable. Polymicrobial bacteremia was also common 
(13.7%).  
The 7- and 30 day crude mortality rates were 5.2% (35/677) and 13.6% (92/677) and polymicrobial 
bacteremia was found in 26% and 18% of those who died within 7 and 30 days, respectively. 
Internationally the death rates were comparable with the literature (128), and the associated increase 
of polymicrobial bacteremia among serious outcomes in neutropenic fever, well known (129). In our 
center practice has been not to give fluoroquinolone-prophylaxis 2002-2008. Nevertheless, we saw a 
significant increment of resistance among E. faecium, Enterobacter spp. and E. coli.; and found more 
resistant E. coli among patient who died within 30-days of bacteremia. 
Fluoroquinolone-prophylaxis use in hematological treatment has remained an issue of discussion. A 
new meta-analysis presented by Imran et al of only placebo controlled trials showed a non-statistically 
reduced mortality risk with fluoroquinolone-prophylaxis in patients with neutropenia (130).  
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Table 1 Bacterial isolates (n=794) and distribution of Gram-positive to gram-negative (53.1% vs 49.9%) between 2002 and 
2008 (58) 
Gram-negative bacilli, 
aerobes 
No.(%
1
) Gram-positive bacteria, aerobes No.(%
1
) 
E. coli 141 (17.8) Coagulase-negative staphylococci 117 (14.7) 
Klebsiella spp. 78 (9.8) Viridans streptococci 111 (14.0) 
Enterobacter spp. 43 (5.4) β-hemolytic streptococci4 15 (2.0) 
Pseudomonas spp. 42 (5.3) E. faecium 61 (7.7) 
Citrobacter spp. 10 (1.3) E. faecalis 11 (1.4) 
Stenotrophomonas maltophilia 6 (0.8) S. aureus 55 (6.9) 
Proteus spp. 3 (0.4) S. pneumonia 18 (2.3) 
Acinetobacter spp. 1 (0.1) Listeria spp. 2 (0.3) 
Haemophilus influenzae 2 (0.3) Bacillus spp. 5 (0.6) 
Morganella spp. 2 (0.3) Enterococcus spp5 3 (0.4) 
Serratia marcescens 1 (0.1) Other gram-positive bacteria6 9 (1.1) 
Other Gram-negative bacilli2 20 (2.5) 
  
  
  Gram-negative anaerobes 
 
Gram-positive anaerobes 
 
Bacteroides spp. 14 (1.8) Clostridium spp.  14 (1.8) 
Fusobacterium spp. 4 (0.5) Other gram-positive anaerobes not typed 1 (0.1) 
Other gram-negative anaerobes3 5 (0.6) 
  
1Due to rounding, not all percentages add up to 100% 
2Other Gram-negative bacilli includes Moraxella spp., Neisseria spp., Capnocytophaga spp., Aeromonas spp., Hafnia alvei, Rosemonas gilardii, Salmonella 
Hadar, Sphingomonas paucimobilis, Gram-negative bacillus not typed;   
3Other Gram-negative anaerobes includes Veillonella spp., Leptotrichia spp., and Gram-negative anaerobes not typed;   
4β-hemolytic streptococci includes β-hemolytic streptococci group A+B+D+G;  
5Enterococcus spp excluding E. faecalis and E. faecium; 
6Other gram-positive bacteria including Lactobacillus spp., Corynebacterium spp. Rothia mucilaginosa, Gram-positive not typed, Stomatococcus 
mucilaginosus, Gemella spp.  
There is a concern of fluoroquinolone prophylaxis leading to more bacterial resistance and more use 
of carbapenems (131). Even so, growing resistance must take the whole community in account when 
evaluating changing patterns (132). Increased resistance can lead to increased mortality and lack off 
prophylactic effect (133). In centers with high resistance discontinuation of prophylaxis has led to 
mixed outcomes regarding infectious complications, but reduced resistance (134, 135). Upon 
reinstitution of prophylaxis, fever episodes and resistance levels reassumed to pre-discontinuation 
levels (136) . 
5.2.2 Study II 
Treatment for CLL has evolved during the last two decades, even more in the last years. Standard 
treatment now constitute not only of chemotherapy, but also of immunotherapy and small molecules 
interfering cell-signaling.  
In study II, the biggest study based on high quality registries on BSI in CLL, we found a decrease in 
positive blood cultures in patients between 1998-2008. We speculate that the more effective treatment 
in recent years, with deeper responses and longer time to next treatment, is behind the reduction of 
positive blood cultures. The distribution of bacterial species was stable, as was the proportion of 
Gram-positive to Gram-negative bacteria which is reassuring. Here again, there has been reports of 
increasing Gram-negative bacteremia as a consequence, most likely, of decrease use of indwelling 
accesses and antibiotic prophylaxis. Dominating BSI pathogens were E. coli, S. pneumoniae, P. 
aeruginosa, S. aureus and viridans streptococci. CoNS was the most frequent detected microorganism 
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in blood cultures, but is a frequent contaminant; and analysis were made with or without common 
contaminants of BSI. 
As intuitively foreseen, we demonstrated that BSI was associated with worse prognosis, especially 
during the last time period. Splenectomies did not affect prognosis for patients with CLL and BSI, but 
power to detect this was hampered by low numbers. We speculate if the introduction of 
immunotherapy could negatively affect the adaptive immune response. By doing that, a BSI 
prevailing the non-specific immune response has a more dismal prognosis. The study is also important 
for future comparisons of infectious complications with the new therapies for CLL that are in late 
phases of clinical trials. 
6 PROSPECTIVE COHORT STUDIES (III, IV) 
6.1 MATERIAL AND METHODS 
6.1.1 Study III 
Patients with hematological malignancies fit for dose-intensive chemotherapy between 2013 and 2014 
at HCK Solna were eligible for enrollment. Patients could be included at any time point during their 
treatment phase, but predominantly and especially for AML, inclusion was made before 
commencement of chemotherapy. In all 33 patients were included in the study; 19 patients with AML 
and 14 with other aggressive hematological malignancies.  
Included patients were sampled with 2 EDTA tubes at different time points; 1) at diagnosis 2) at 
neutropenic fever before initiation of antibiotics 3) follow-up samples to fever-onset sample (only for 
AML), and 4) persisting fever during broad spectrum antibiotic treatment. Patient data was extracted 
retrospectively.  
Bacterial DNA extraction was done within 1-24 hours with MolYsis Complete 5 kit (Molzym Life 
Science, Bremen, Germany). All samples were checked for 16S rRNA gene positivity. Positive 
samples were then subject for library preparation with primer pair covering the V1-V3 regions of the 
16S rRNA, and processed to a 2x300bp paired end (PE) sequencing on an Illumina MiSeq instrument. 
Reads below Q20 and 246bp, and unmerged PE and chimeras were removed. Subsequent overlapping 
PE reads were merged and phylogenetically analysed. Abundance was calculated from reads within 
the different clusters. Presentation of bacteria in the study required sample to contain at least 0.5% of 
the total operational taxonomic unit (OTU)-assigned reads in each sample.  
6.1.2 Study IV 
From the same cohort as in study III, 8 out of 19 patients with AML that had full availability of results 
from inclusion, fever onset, and follow up samples were selected for shotgun metagenomics. 
Bacterial content was extracted with MolYsis and 1 µg eluted DNA was enriched with NebNext (New 
England Biolabs, Ipwich, MA, USA). 10 ng DNA was then subject for multiplex displacement 
amplification and 2 µg for library preparation with Nextera XT Kit and subsequently sequenced on 
HiSeq 2500 instrument. Received data reads were then bioinformatically processed using the Fastx 
toolkit; for disregarding shorter than 30bp reads and low quality reads; Flash software merged PEs 
and, RTG Core 3.4 was used to map sequencing reads against microbial databases and to filter against 
the human genome. The ARG-ANNOT database was used to detect antibiotic resistance genes and the 
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gene ontology analysis was completed using the Blast2Go v3 software. Mann-Whitney U-test was 
performed to detect statistical significance. 
6.2 RESULTS AND DISCUSSION  
6.2.1 Study III 
Standard diagnostics for BSI, mainly blood culture and PCR-techniques has several limitations as 
already stated. NGS is a quickly growing field, allowing billions of reads in a few days’ time. At the 
time of publication, the bacterial landscape of bloodstream infections in patients with hematological 
malignancies and neutropenia was unexplored. 
130 samples were analysed; 27 from AML patients at diagnosis, 38 at fever onset, 41 during follow up 
and 24 due to persistent fever (Figure 8). 16SrRNA positivity was 23.7% (9/38) for fever onset, 7.3% 
(3/41) for follow up and 29.2% (7/24) for persisting fever and in none of the inclusion samples. Blood 
cultures were positive in 15.4% (10/65); 21.1% (8/38) at fever onset and 8.3% (2/24) in persisting 
fever and none in follow up samples.  
Sequencing yielded 2,764,592 reads assigned to bacterial OTUs. Five bacterial phyla: 55.2% 
Proteobacteria (Gram-negative bacteria like Pseudomonas and Escherichia), 33.4% Firmicutes 
(mostly Gram-positive normal flora like Staphylococus and Streptococcus, 8.6% Actinobacteria 
(Gram-positive bacteria found in the environment, potentially opportunistic pathogens like 
Corynbacterium), Fusobacterium 0.4% (anaerob Gram-negative potentially opportunistic pathogens 
normally found in the oral flora, like Leptotrichia and Fusobacterium) and 0.1% Bacteroidetes 
(Gram-negative bacteria in soil, gut and oral flora; potentially opportunistic pathogens like 
Alloprevatella and Bacteroides) (Figure 9). 
Figure 9. Distribution of phyla from sequences in all samples (A) per sample (B) 
and from those with positive blood culture (C) (137). 
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From the 5 phyla, 30 genera were identified and all previously isolated from BSI, except Pelomonas, 
which, however recently was found in the endometrial bacterial community (138) (Figure 10). The 
notion that identified bacteria belonged to the normal human microbiota supports the idea of 
translocation of bacteria playing a pivotal role in inflammation associated with sepsis. Another notion 
is that the Shewanella genus (previously Pseudomonas) was detected in 80% of the samples. 
Shewanella bacteremia, although well described, is not routinely diagnosed with standard methods 
and could constitute one of more underdiagnosed microorganisms in BSI found in our material. 
NGS was also able to estimate efficacy of antibiotics, calculated as change in reads, but also identify 
bacterial DNA content in patients with ongoing antibiotics, as shown in the persisting fever group 
when comparing NGS with blood cultures. This is most probably due to non-cleared non-functional 
bacterial DNA in the blood. This type of translocation of bacterial content is most likely to be 
involved in the host’s response to bacteria, and might thereby help our understanding of sepsis.  
Figure 10. Bacteria on the species level detected with NGS (137). 
6.2.2 Study IV 
As expected with shotgun metagenomics, analysis yielded more reads, compared to the 16sRNA 
study. Out of the 27 samples; 1 sample was from inclusion, 9 samples were from fever onset (day 0, 
before antibiotic treatment), 7 samples were from the day after antibiotic commenced, and 11 samples 
were from day 1-5. In 2 patients no microbial content was found (Figure 11). No microorganism was 
detected in 2 of the fever onset samples, in 1 of the persistent fever samples and in 6 of the follow up 
samples. 
Antibacterial treatment only caused, as foreseen, a significant effect on Shannon’s diversity index for 
bacteria. In follow up samples bacterial reads were very low. 
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Figure 11. (A) Distribution of sequencing reads. (B) Distribution microbes detected by NGS. Sample 
category in color and numbers reflecting occurrence (139). 
Distribution of reads for bacteria, fungi and viruses are depicted in Figure 12. Propionbacterium acnes 
dominated in fever samples, but was not found at all in follow up samples. Persistent fever samples 
were dominated by Corynbacterium spp., Dolosigranum pigrum and Staphylococcus spp.. All species 
should have been susceptible to given antibiotics, and a contamination can therefore not be ruled out. 
The most reoccurring bacteria in persistent fever samples was Streptococcus spp., also covered by 
given antibiotics, could mean a reinfection as the reads were repeatedly low in these samples. 
Acinetobacter, known for acquiring resistance mechanisms was found in 5 samples from 2 patients, 
and most reads were found among samples obtained at persistent fever. Fusarium oxysporum reads 
dominated and was the most frequent fungi at all time-points for sampling. Also, Aspergillus spp. was 
detected in one sample with persistent fever. All patients received posaconazole, known to be 
effective against Aspergillus spp. but resistance can occur against Fusarium spp.. Phages, most 
probably resulting from dead bacteria, were more common in persistent fever than fever onset. No 
certain neutropenia specific virus was detected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. (A) Distributions of bacterial reads at different time points (bacterial taxa with reads of <1% in a sample not 
shown) (B) fungal reads (C) and viral reads. Numbers within the pie charts indicate the number of samples positive for the 
given pathogen (139).  
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7 CONCLUDING REMARKS 
From the retrospective studies, first on a diverse cohort of hematological malignancies and later on a 
CLL-specific cohort, we have found stable distribution of pathogens and mortality over time; 
corroborating other international reports. The reported increase in fluoroquinolone-resistant E. coli in 
blood cultures is in parallel with the trend in our hospital, and nationally reported data. It is my 
personal opinion that the more liberal use in the last decade of fluoroquinolone-prophylaxis in 
hematological malignancies lacks good scientific support. In awaiting future prospective comparative 
trials fluoroquinolone-prophylaxis should only be used for the very high risk patients. For optimal use 
of antibiotics; more should be done for endorsing adherence to existing guidelines and development of 
technical tools aiding clinical work. 
Next generation sequencing, as opposed to traditional infectious disease diagnostics, requires little or 
no prior knowledge of possible findings. Our prospective studies have given us novel insight into 
unculturable bacteria as well as culturable microorganisms; and dynamics of infectious episodes. 
Clinically, many microbiological diagnostic methods can be replaced by NGS. However, NGS for 
microbial detection need to improve in: timeliness, cost, sensitivity, discriminative power, and 
complexity of data analysis and interpretation; before being clinical useful. Nonetheless, it is my belief 
that NGS in the future will learn us much more about the important microbiome-host interaction, the 
panorama of pathogenic microorganisms and their management.  
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Blodcancer är den fjärde vanligaste cancerformen och en ledande orsak till cancerrelaterad död i 
Sverige. Patienter med blodcancer tvingas ofta till tuffa behandlingar, som i princip alltid upprepas 
under lång tid. Grundsjukdomen och dess behandlingar; ofta kombinationer av cellgifter, strålterapi, 
målstyrda antikroppar och stamcellstransplantation, leder till sänkt immunförsvar. Nedsatt 
immunförsvar är förenat med infektioner som i sin tur kan leda till exempelvis blodförgiftning, sänkt 
livskvalité och ökad risk för ohälsa och död. Att drabbas av en blodförgiftning med virus, svamp eller 
bakterie tillhör den absolut allvarligaste infektionskomplikationen som patienter med hematologisk 
malignitet kan drabbas av. Utan korrekt antimikrobiell behandling ökar dödligheten markant för varje 
timme. Dagens diagnostiska metoder för blodförgiftning vilka är relativt oförändrade under de senaste 
decennierna, är långsamma och fångar upp bara en bråkdel av attackerande mikroorganismer. Även 
om förebyggande antimikrobiell behandling med till exempel antibiotikaprofylax minskar risken för 
infektiösa komplikationer är risken ändå inte försumbar. I händelse av misstänkt infektion tvingas 
därför ofta behandlande läkare att inleda kraftfull antimikrobiell behandling innan svar på eventuell 
mikrobiologisk diagnostik finns tillgängligt. Hög antibiotikaförbrukning leder till ökad 
antibiotikaresistens, som i sin tur leder till minskad effekt av antibiotikabehandling och därmed ökad 
dödlighet. För att förbättra vården vid blodförgiftning är det viktigt att ha god kunskap om vilka 
mikrobiella organismer som drabbar patienterna, att känna till antibiotikaresistensläget bland vanliga 
bakteriefynd och att utveckla bättre diagnostiska verktyg. 
År 2003 publicerades mikrobiologiska fynd vid blododlingar tagna 1988-2001 på hematologens 
slutenvårdavdelning vid Karolinska Universitetssjukhuset i Solna. Studien påvisade i huvudsak stabil 
distribution av bakteriella arter i blododlingar och oförändrad låg förekomst av antibiotikaresistens. 
Nya studier 2003-2008 beskrev ökad resistensproblematik såväl nationellt som internationellt, och vår 
restriktiva strategi avseende antibiotikaprofylax kunde ifrågasättas. 
Studie I beskriver blododlingsfynd hos patienter med hematologisk malignitet som vårdats på 
hematologens slutenvårdavdelning vid Karolinska Universitetssjukhuset i Solna 2002-2008. I Studie I 
jämförs också nämnda resultat med historiska data (1980-2001) från samma institution. Återigen 
noteras stabil distribution av bakteriella arter, en viss ökning av antibiotikaresistens hos tarmbakterier 
såsom E. coli, Enterobacter spp. och Enterococcus faecium. Studien visar att flera olika bakterier i 
blodet vid blodförgiftning är vanligt förekommande och förenat med ökad dödlighet. Dödligheten 7 
respektive 30 dagar efter en blodförgiftning är låg, även vid en internationell jämförelse. Dödligheten 
är ökad hos patienter med resistent E. coli i blodet jämfört med patienter med E. coli utan 
resistensproblematik. Studien bekräftar också att det inte fanns några tecken på att vi under aktuell 
period borde ha övergivit vår kliniks restriktiva antibiotikaprofylaxpolicy.  
Kronisk lymfatisk leukemi (KLL) är den vanligaste kroniska leukemin i västvärlden. 
Cancerbehandlingen mot KLL har under åren förändrats. Inte minst på senare år har flera nya 
behandlingsalternativ tillkommit. Studie II utgår från patienter som påvisats ha en bakterie i blodet 
vid analys på Mikrobiologen vid Karolinska Universitetssjukhuset, 1988-2003. Studie II visar att E. 
coli, S. pneumoniae, Pseudomonas aeruginosa, S. aureus, och viridans streptococci är de vanligast 
förekommande bakterierna vid blodförgiftning vid KLL. Resultaten från studien kommer att fungera 
som viktig referens i framtiden, då nya cancerbehandlingars komplikationer i form av 
blodförgiftningar ska analyseras.  
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I studie III tillämpas en ny teknologi för att identifiera arvsanlag från bakterier i blodet. Prov från 
patienter med hematologisk malignitet och nedsatt immunförsvar togs i samband med feber. 
Traditionell diagnostik av blodförgiftningar, d.v.s. blododlingar, begränsas av att alla bakterier inte 
lika lätt tillåter sig att odlas fram och att det är svårt med blododling att påvisa mer än en bakterie. 
Med den nya tekniken, som vi är först i världen med att applicera på hematologiska patienter med 
infektion, kunde fler bakterier identifieras, även under pågående antibiotikabehandling. Studien ger en 
fingervisning om mekanismer som kan vara aktuella för de patienter som har kvarstående feber trots 
tillsynes korrekt antibiotikabehandling. 
I Studie IV använde vi snarlik teknologi som i studie III, men här letade vi förutom efter arvsanlag 
från bakterier i blodet även efter arvsanlag från svampar och virus. Studien beskriver bland annat 
dynamiken vid feberepisoder, d.v.s. hur förekomst av infektionsalstrande mikroorganismers arvsanlag 
stiger och sjunker i blodet som svar på antimikrobiell behandling. Vidare ges spekulativa förklaringar 
till några av de episoder av oförklarlig feber trots kraftfull antimikrobiell behandling som vi som 
kliniker ser hos denna patientgrupp.  
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